CoChat

Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium

Open access

The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.

Abstract

Background: Successful treatment of major depressive disorder (MDD) can be challenging, and failures ("treatment-resistant depression" [TRD]) are frequent. Steps to address TRD include increasing antidepressant dose, combining antidepressants, adding adjunctive agents, or using nonpharmacological treatments. Their relative efficacy and tolerability remain inadequately tested. In particular, the value and safety of increasingly employed second-generation antipsychotics (SGAs) and new esketamine, compared to lithium as antidepressant adjuncts remain unclear. Methods: We reviewed randomized, placebo-controlled trials and used random-effects meta-analysis to compare odds ratio (OR) versus placebo, as well as numbers-needed-to-treat (NNT) and to-harm (NNH), for adding SGAs, esketamine, or lithium to antidepressants for major depressive episodes. Results: Analyses involved 49 drug-placebo pairs. By NNT, SGAs were more effective than placebo (NNT = 11 [CI: 9–15]); esketamine (7 [5–10]) and lithium (5 [4–10]) were even more effective. Individually, aripiprazole, olanzapine+fluoxetine, risperidone, and ziprasidone all were more effective (all NNT < 10) than quetiapine (NNT = 13), brexpiprazole (16), or cariprazine (16), with overlapping NNT CIs. Risk of adverse effects, as NNH for most-frequently reported effects, among SGAs versus placebo was 5 [4–6] overall, and highest with quetiapine (NNH = 3), lowest with brexpiprazole (19), 5 (4–6) for esketamine, and 9 (5–106) with lithium. The risk/benefit ratio (NNH/NNT) was 1.80 (1.25–10.60) for lithium and much less favorable for esketamine (0.71 [0.60–0.80]) or SGAs (0.45 [0.17–0.77]). Conclusions: Several modern antipsychotics and esketamine appeared to be useful adjuncts to antidepressants for acute major depressive episodes, but lithium was somewhat more effective and better tolerated. Limitations: Most trials of adding lithium involved older, mainly tricyclic, antidepressants, and the dosing of adjunctive treatments were not optimized.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/02698811211013579

Cites

81 of 81 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Forest plots of random-effects meta-analyses for clinical trials testing the efficacy of supplementing antidepressants with active agents or placebo for major depression: (a) second-generation antipsychotics (SGAs, 28 trials), (b) intranasal esketamine (7 trials), or (c) lithium carbonate (13 trials). SGAs tested were: APZ, aripiprazole; BRX, brexpiprazole; CAR, cariprazine; OFC, olanzapine+fluoxetine combination; QTP, quetiapine; RSP, risperidone; ZPS, ziprasidone. Adding all three types of active treatments were much more effective than adding placebo: (a) SGAs: pooled OR = 1.59 [CI: 1.44–1.75]; z-score = 9.16, p < 0.0001; (b) esketamine: pooled OR = 1.85 [1.45–2.35]; z-score = 4.98, p < 0.0001; Lithium: pooled OR = 2.12 [1.46–3.09]; z = 3.92, p < 0.0001. Heterogeneity ratings (I2) all were <1.0%.
Figure 1. Forest plots of random-effects meta-analyses for clinical trials testing the efficacy of supplementing antidepressants with active agents or placebo for major depression: (a) second-generation antipsychotics (SGAs, 28 trials), (b) intranasal esketamine (7 trials), or (c) lithium carbonate (13 trials). SGAs tested were: APZ, aripiprazole; BRX, brexpiprazole; CAR, cariprazine; OFC, olanzapine+fluoxetine combination; QTP, quetiapine; RSP, risperidone; ZPS, ziprasidone. Adding all three types of active treatments were much more effective than adding placebo: (a) SGAs: pooled OR = 1.59 [CI: 1.44–1.75]; z-score = 9.16, p < 0.0001; (b) esketamine: pooled OR = 1.85 [1.45–2.35]; z-score = 4.98, p < 0.0001; Lithium: pooled OR = 2.12 [1.46–3.09]; z = 3.92, p < 0.0001. Heterogeneity ratings (I2) all were <1.0%.CC BY-NC · PubMed Central
Figure A1. Flow-chart of selection of reports for inclusion in study, based on PRISMA recommendations (http://www.prisma-statement.org/PRISMAStatement/PRISMAStatement) to yield 39 reports (with 43 trials) included for analysis.
Figure A1. Flow-chart of selection of reports for inclusion in study, based on PRISMA recommendations (http://www.prisma-statement.org/PRISMAStatement/PRISMAStatement) to yield 39 reports (with 43 trials) included for analysis.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 81 references

Cited by

See all 101

Metadata

Authors
Vázquez, G. H., Bahji, A., Undurraga, J., Tondo, L., & Baldessarini, R. J.
Affiliations
  • Queen's University (CA)
  • University of Calgary (CA)
  • Universidad del Desarrollo (CL)
  • Harvard University (US)
Corresponding author
Vázquez, Gustavo H.
Venue
Journal of Psychopharmacology
Published
2021-07-09
Volume
35
Issue
8
Pages
890-900
ISSN
  • 0269-8811 (ISSN-L)
  • 1461-7285
OpenAlex
W3182403469
Cited by
95
References
81
Citations by year
2026: 12 · 2025: 17 · 2024: 21 · 2023: 24 · 2022: 18 · 2021: 3
FWCI
9.63
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Psychopharmacology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • aretaeus foundation of rome (ANID-PIA-ACT192064)
  • Centro Bini Private Donors Research Fund (ANID-FONDECYT 1180358, ANID-FONDECYT 1200601)
  • clínica alemana de santiago (ID 863)
  • Bruce J. Anderson Foundation
  • McLean Private Donors Research Fund
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
Keywords
major depressive disorder, antidepressant augmentation, atypical antipsychotics, esketamine, lithium, aripiprazole, olanzapine, risperidone, quetiapine, brexpiprazole, cariprazine, ziprasidone, efficacy, tolerability, risk-benefit ratio, adverse effects
MeSH terms
Antidepressive Agents, Depressive Disorder, Major, Major Depressive Disorder, Dose-Response Relationship, Drug, Drug Therapy, Combination, Humans, Ketamine, Antipsychotic Agents, Randomized Controlled Trials as Topic, Lithium Compounds, Depressive Disorder, Treatment-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium. https://app.cochat.ai/papers/10.1177/02698811211013579
The paper
Vázquez, G. H., Bahji, A., Undurraga, J., Tondo, L., & Baldessarini, R. J. (2021). Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium. Journal of Psychopharmacology. https://doi.org/10.1177/02698811211013579

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.